Literature DB >> 34705141

ASO Author Reflections: Bi-Directional Chemotherapy Using PIPAC Could Downstage Nonresectable Malignant Peritoneal Mesothelioma Patients to a Complete Resection.

Vahan Kepenekian1,2, Julien Péron3,4, Benoit You5,3, Olivier Glehen6,5.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34705141     DOI: 10.1245/s10434-021-10990-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  4 in total

Review 1.  Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications.

Authors:  Mohammad Alyami; Martin Hübner; Fabian Grass; Naoual Bakrin; Laurent Villeneuve; Nathalie Laplace; Guillaume Passot; Olivier Glehen; Vahan Kepenekian
Journal:  Lancet Oncol       Date:  2019-07       Impact factor: 41.316

2.  Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy.

Authors:  Florence Le Roy; Maximiliano Gelli; Antoine Hollebecque; Charles Honoré; Valerie Boige; Peggy Dartigues; Leonor Benhaim; David Malka; Michel Ducreux; Dominique Elias; Diane Goéré
Journal:  Ann Surg Oncol       Date:  2017-08-28       Impact factor: 5.344

3.  Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cyoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

Authors:  Niharika Rajan Garach; Shigeki Kusamura; Marcello Guaglio; Valentina Bartolini; Marcello Deraco; Dario Baratti
Journal:  Eur J Surg Oncol       Date:  2020-08-25       Impact factor: 4.424

4.  ASO Visual Abstract: Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study.

Authors:  Vahan Kepenekian; Julien Péron; Benoit You; Isabelle Bonnefoy; Laurent Villeneuve; Mohammad Alyami; Naoual Bakrin; Pascal Rousset; Nazim Benzerdjeb; Olivier Glehen
Journal:  Ann Surg Oncol       Date:  2022-03       Impact factor: 5.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.